This Alnylam promotional website is intended for UK Healthcare Professionals Only. Adverse Event Reporting information can be found at the bottom of the page. Prescribing Information links can be found with the content that they relate to.
Transthyretin Amyloidosis (ATTR)
Transthyretin Amyloidosis (ATTR) is an underdiagnosed, rapidly progressing, fatal, multisystem disease, caused by misfolded TTR accumulating as amyloid deposits in multiple organs. Patients with ATTR amyloidosis experience progressively debilitating symptoms and high morbidity and mortality rates, making early diagnosis and intervention vital.1–4
Resources
Presentation
Therapies
ONPATTRO® (patisiran)
Explore clinical and educational resources related to the use of patisiran in adult patients hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with stage 1 or stage 2 polyneuropathy.
AMVUTTRA®
(vutrisiran)
Explore clinical and educational resources related to the use of vutrisiran in adult patients with hereditary transthyretin amyloidosis with stage 1 or stage 2 polyneuropathy (hATTR-PN) or wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Congresses
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2025
Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Publications
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
References:
- Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Ann Med. 2015;47(8):625-638.
- Gertz MA. Am J Manag Care. 2017;23(7):S107-S112.
- Conceicao I, Gonzalez-Duarte A, Obici L, et al. J Peripher Nerv Syst. 2016;21:5-9.
- Ando Y, Coehlo T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.
Preparation Date: January 2026 Job Code: MB-UK-00040
